The clinical outcomes of intravitreal dexamethasone implant as the first-line treatment in retinal vein occlusion related macular edema
References
251 citations
183 citations
"The clinical outcomes of intravitre..." refers background in this paper
...Proinflammatory cytokines are also involved in augmentation of macular edema (1,2)....
[...]
...8 (4, 2-6) months while cataract progression (70....
[...]
...Similarly, BCVA values significantly improved on the 1st month and although there were some alterations through the worse side on 5th-6th and 11th-12th months, these values were still significantly Ann Med Res 2019;26(2):255-9...
[...]
51 citations
"The clinical outcomes of intravitre..." refers background in this paper
...(13) reported that 56% of patients relapsed after first injection and the median time to relapse was 17 weeks....
[...]
...In another retrospective study on 51 eyes with RVO- associated macular edema, Joshi et al. (13) reported that 56% of patients relapsed after first injection and the median time to relapse was 17 weeks....
[...]
44 citations
"The clinical outcomes of intravitre..." refers background in this paper
...8 (4, 2-6) months while cataract progression (70....
[...]
...Moreover, they have short-term effects and repeated injections may be required (3-5)....
[...]
43 citations
"The clinical outcomes of intravitre..." refers background in this paper
...7 mg (DEX implant; Ozurdex®, Allergan plc, Dublin, Ireland) has been shown to be effective in treating macular edema secondary to RVO (6,7)....
[...]